Login
Registrati
Reimposta password
Pubblica & Distribuisci
Soluzioni Editoriali
Soluzioni di Distribuzione
Temi
Architettura e design
Arti
Business e Economia
Chimica
Chimica industriale
Farmacia
Filosofia
Fisica
Geoscienze
Ingegneria
Interesse generale
Legge
Letteratura
Linguistica e semiotica
Matematica
Medicina
Musica
Scienze bibliotecarie e dell'informazione, studi library
Scienze dei materiali
Scienze della vita
Scienze informatiche
Scienze sociali
Sport e tempo libero
Storia
Studi classici e del Vicino Oriente antico
Studi culturali
Studi ebraici
Teologia e religione
Pubblicazioni
Riviste
Libri
Atti
Editori
Blog
Contatti
Cerca
EUR
USD
GBP
Italiano
English
Deutsch
Polski
Español
Français
Italiano
Carrello
Home
Riviste
The EuroBiotech Journal
Volume 3 (2019): Numero 2 (April 2019)
Accesso libero
Future Biotechnology
Munis Dundar
Munis Dundar
,
Satya Prakash
Satya Prakash
,
Ratnesh Lal
Ratnesh Lal
e
Donald K. Martin
Donald K. Martin
| 24 apr 2019
The EuroBiotech Journal
Volume 3 (2019): Numero 2 (April 2019)
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Sommario
Articolo
Immagini e tabelle
Bibliografia
Autori
Articoli in questo Numero
Anteprima
PDF
Cita
CONDIVIDI
Article Category:
Review
Pubblicato online:
24 apr 2019
Pagine:
53 - 56
DOI:
https://doi.org/10.2478/ebtj-2019-0006
Parole chiave
Medical biotechnology
,
nanotechnology
,
genetics
,
future developments
© 2019 Munis Dundar, Satya Prakash, Ratnesh Lal, Donald K. Martin, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Figure 1
Overview of the human genome. Gene and gene-related sequences cover 37.5% of the human genome, while genome-wide repeats constitute 43.75%. The remaining 18.75% are intergenic regions.
Figure 2
Examples of symbio-bots (A–D) that can be created in a bioinspired way (E). Each device is separated with a smart porous packaging that allows a duplex communication. Therapeutic cells (A and B) need a porous encapsulation that avoids an immune reaction and allows protection from both sides. They may be human cells, as MSC or specialized cells such as β-cell from Langherans islets (A), or other eukaryotic or prokaryotic cells (B). Panel C shows an IBFC linked to an electronic medical device. Panel D shows a generic device delivering a therapeutic molecule. Panel E: Existing symbiosis (i.e., microbiota or pregnancy) are a source of bio-inspiration to establish a duplex communication between the body and its implants. Regenerative medicine should embrace this concept of bioinspiration for a better design and integration of implants, especially for future symbio-bots. (reproduced with permission from Alcaraz et al (10)).